vTv Therapeutics

$1.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.52%) Today
-$0.03 (-1.56%) As of 4:21 PM EST after-hours

Why Robinhood?

You can buy or sell VTVT and other stocks, options, and ETFs commission-free!

About VTVT

vTv Therapeutics Inc. Class A Common Stock, also called vTv Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC. The listed name for VTVT is vTv Therapeutics Inc. Class A Common Stock.

CEO
Stephen L. Holcombe
Employees
26
Headquarters
High Point, North Carolina
Founded
2015
Market Cap
97.51M
Price-Earnings Ratio
Dividend Yield
Average Volume
614.45K
High Today
$1.97
Low Today
$1.87
Open Price
$1.96
Volume
457.16K
52 Week High
$4.23
52 Week Low
$1.44

Collections

VTVT Earnings

-$0.11
-$0.07
-$0.04
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 18, After Hours

You May Also Like